Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis

References

• Goff KL, Karimkhani C, Boyers LN, et al. The global burden of psoriatic skin disease. Br J Dermatol. 2015;172(6):1665–1668.
   Google Scholar
• Orciani M, Campanati A, Salvolini E, et al. The mesenchymal stem cell profile in psoriasis. Br J Dermatol. 2011;165(3):585–592.
   Google Scholar
• Campanati A, Orciani M, Sorgentoni G, et al. Indirect co-cultures of healthy mesenchymal stem cells restore the physiological phenotypical profile of psoriatic mesenchymal stem cells. Clin Exp Immunol. 2018;193(2):234–240.
   Google Scholar
• Campanati A, Orciani M, Consales V, et al. Characterization and profiling of immunomodulatory genes in resident mesenchymal stem cells reflect the Th1-Th17/Th2 imbalance of psoriasis. Arch Dermatol Res. 2014;306(10):915–920.
   Google Scholar
• World Health Organization. Psoriasis. Agenda item 13.5. World Health Assembly: Geneva, Switzerland; 2014.
   Google Scholar
• Tsai TF, Wang TS, Hung ST, et al. Epidemiology and comorbidities of psoriasis patients in a national database in taiwan. J Dermatol Sci. 2011;63:40–46.
   Google Scholar
• Zeng J, Luo S, Huang Y, et al. Critical role of environmental factors in the pathogenesis of psoriasis. J Dermatol. 2017;44(8):863–872.
   Google Scholar
• Bo K, Thoresen M, Dalgard F. Smokers report more psoriasis, but not atopic dermatitis or hand eczema: results from a norwegian population survey among adults. Dermatology. 2008;216:40–45.
   Google Scholar
• Liu JT, Yeh HM, Liu SY, et al. Psoriatic arthritis: epidemiology, diagnosis, and treatment. World J Orthop. 2014;5(4):537–543.
   Google Scholar
• Ogdie A, Langan S, Love T, et al. Prevalence and treatment patterns of psoriatic arthritis in the UK. Rheumatology. 2013;52:568–575.
   Google Scholar
• Salaffi F, Di Carlo M, Luchetti MM, et al. A validation study of the simple psoriatic arthritis screening (SiPAS) questionnaire to screen psoriasis patients for psoriatic arthritis. Clin Exp Rheumatol. 2018;36(1):127–135.
   Google Scholar
• Piaserico S, Gisondi P, Amerio P, et al. Validation and field performance of the italian version of the psoriatic arthritis screening and evaluation (PASE) questionnaire. D Acta Derm Venereol. 2016;96(217):96–101.
   Google Scholar
• Campanati A, Neri P, Giuliodori K, et al. Psoriasis beyond the skin surface: a pilot study on the ocular involvement. Int Ophthalmol. 2015;35(3):331–340.
   Google Scholar
• Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9–20.
   Google Scholar
• Ganzetti G, Campanati A, Offidani A. Non-alcoholic fatty liver disease and psoriasis: so far, so near. World J Hepatol. 2015;7(3):315–326.
   Google Scholar
• Ganzetti G, Campanati A, Molinelli E, et al. Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: three different diseases on a unique background. World J Cardiol. 2016;8(2):120–131.
   Google Scholar
• Giannoni M, Consales V, Campanati A, et al. Homocysteine plasma levels in psoriasis patients: our experience and review of the literature. J Eur Acad Dermatol Venereol. 2015;29(9):1781–1785.
   Google Scholar
• Gisondi P, Cazzaniga S, Chimenti S, et al. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian psocare registry. J Eur Acad Dermatol Venereol. 2013;27(1):e30–41.
   Google Scholar
• Ferretti G, Bacchetti T, Campanati A, et al. Correlation between lipoprotein(a) and lipid peroxidation in psoriasis: role of the enzyme paraoxonase-1. Br J Dermatol. 2012;166(1):204–207.
   Google Scholar
• Campanati A, Ganzetti G, Giuliodori K, et al. Biologic therapy in psoriasis: safety profile. Curr Drug Saf. 2016;11(1): 4–11. Review.
   Google Scholar
• Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019 Jan;80(1):43–53.
   Google Scholar
• Rønholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18(11):2297. Review.
   Google Scholar
• Campanati A, Orciani M, Lazzarini R, et al. TNF-α inhibitors reduce the pathological Th1-Th17/Th2 imbalance in cutaneous mesenchymal stem cells of psoriasis patients. Exp Dermatol. 2017;26(4):319–324.
   Google Scholar
• Campanati GM, Ganzetti G, Pozniak KN, et al. Adalimumab modulates angiogenesis in psoriatic skin. Eur J Inflammation. 2013;11(2):489–498.
   Google Scholar
• Campanati A, Goteri G, Simonetti O, et al. CTACK/CCL27 expression in psoriatic skin and its modification after administration of etanercept. Br J Dermatol. 2007;157(6):1155–1160.
   Google Scholar
• Campanati A, Goteri G, Simonetti O, et al. Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation. Int J Immunopathol Pharmacol. 2009;22(2):371–377.
   Google Scholar
• Campanati A, Orciani M, Gorbi S, et al. Effect of biologic therapies targeting tumour necrosis factor-α on cutaneous mesenchymal stem cells in psoriasis. Br J Dermatol. 2012;167(1):68–76.
   Google Scholar
• Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: a comprehensive review. J Autoimmun. 2015;64:66–73.
   Google Scholar
• Liang Y, Sarkar MK, Tsoi LC, et al. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr Opin Immunol. 2017;49: 1–8. Epub 2017 Jul 22. Review.
   Google Scholar
• Morizane S, Gallo RL. Antimicrobial peptides in the pathogenesis of psoriasis. J Dermatol. 2012;39:225–230.
   Google Scholar
• Morizane S, Yamasaki K, Muhleisen B, et al. Cathelicidin antimicrobial peptide ll-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. J Investig Dermatol. 2012;132:135–143.
   Google Scholar
• Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005;202:135–143.
   Google Scholar
• Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol. 2015;11:415–429.
   Google Scholar
• Nestle FO, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells in psoriasis. Autostimulation of t lymphocytes and induction of th1 type cytokines. J Clin Investig. 1994;94:202–209.
   Google Scholar
• Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017 Sep;140(3):645–653.
   Google Scholar
• Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, et al. Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131:677–687.
   Google Scholar
• Ghoreschi K, Laurence A, Yang XP, et al. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature. 2010;467:967–971.
   Google Scholar
• van Beelen AJ, Teunissen MB, Kapsenberg ML, et al. Interleukin-17 in inflammatory skin disorders. Curr Opin Allergy Clin Immunol. 2007;7:374–381.
   Google Scholar
• Wilsmann-Theis D, Schnell LM, Ralser-Isselstein V, et al. Successful treatment with interleukin-17a antagonists of generalized pustular psoriasis in patients without IL36RN mutations. J Dermatol. 2018;45:850–854.
   Google Scholar
• Sakkas LI, Bogdanos DP. Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data. Autoimmun Rev. 2017;16:10–15.
   Google Scholar
• Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119(3):651–665.
   Google Scholar
• Bach E, Nielsen RR, Vendelbo MH, et al. Direct effects of TNF-α on local fuel metabolism and cytokine levels in the placebo-controlled, bilaterally infused human leg: increased insulin sensitivity, increased net protein breakdown, and increased IL-6 release. Diabetes. 2013;62(12):4023–4029.
   Google Scholar
• Smookler DS, Mohammed FF, Kassiri Z, et al. Tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J Immunol. 2006;176(2):721–725.
   Google Scholar
• Parameswaran N, Patial S. Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryot Gene Expr. 2010;20(2):87–103.
   Google Scholar
• Horiuchi T, Mitoma H, Harashima S, et al. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford). 2010;49(7):1215–1228.
   Google Scholar
• Eissner G, Kolch W, Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev. 2004;15:353–366.
   Google Scholar
• Vergou T, Moustou AE, Sfikakis PP, et al. Pharmacodynamics of TNF-α inhibitors in psoriasis. Exp Rev Clin Pharmacol. 2011;4(4):515–523.
   Google Scholar
• Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244–279.
   Google Scholar
• Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204:3183–3194.
   Google Scholar
• Campanati A, Ganzetti G, Di Sario A, et al. The effect of etanercept on hepatic fibrosis risk in patients with non-halcolic fatty liver disease, metabolic syndrome, and psoriasis. J Gastroenterol. 2013;48(7):839–846.
   Google Scholar
• Prattichizzo F, Giuliani A, Recchioni R, et al. Anti-TNF-α treatment modulates SASP and SASP-related microRNAs in endothelial cells and in circulating angiogenic cells. Oncotarget. 2016;7(11):11945–11958.
   Google Scholar
• Campanati A, Orciani M, Ganzetti G, et al. The effect of etanercept on vascular endothelial growth factor production by cutaneous mesenchymal stem cells from patients with psoriasis. J Int Med Res. 2016;44(1 suppl):6–9.
   Google Scholar
• Liu H, Gaza-Bulseco G, Faldu D, et al. Heterogenity of monoclonal antibodies. J Pharm Sci. 2008;97:2426–2447.
   Google Scholar
• De Simone C, Amerio P, Amoruso G, et al. Prestinari; Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue? F. Expert Opin Biol Ther. 2013;13(12):1673–1682.
   Google Scholar
• Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002 May;301(2):418–426.
   Google Scholar
• Kohno T, Tam LT, Stevens SR, et al. Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs. J Investig Dermatol Symp Proc. 2007 May;12(1):5–8.
   Google Scholar
• Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995;7:251–259.
   Google Scholar
• Krüger-Krasagakis S, Galanopoulos VK, Giannikaki L, et al. Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis. Br J Dermatol. 2006;154(3):460–466.
   Google Scholar
• Bedini C, Nasorri F, Girolomoni G, et al. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function. Br J Dermatol. 2007;157(2):249–258.
   Google Scholar
• Remicade ® (infliximab) [Prescribing information]. Horsham, PA: Janssen Biotech, Inc.
   Google Scholar
• FDA. Package insert humira ® (adalimumab). U.S. Govt. Lic. No. 0043, Abbott Laboratories; 2002 [Cited 2009 Mar 24]. Available from: http://www.fda.gov/Cder/foi/label/2002/adalabb123102LB.htm
   Google Scholar
• Mensà E, Recchioni R, Marcheselli F, et al. MiR-146a-5p correlates with clinical efficacy in patients with psoriasis treated with the tumour necrosis factor-alpha inhibitor adalimumab. Br J Dermatol. 2018;179(3):787–789.
   Google Scholar
• European Medicines Agency. Humira ®: procedural steps taken and scientific information after the authorisation. London, United Kingdom. 2016.
   Google Scholar
• Kohno T, Edwards CK, Sonnenber GM. Biacore analysis of receptor binding with covalently and non-covalently associated TNFa. 64th Annual Scientific Meeting of the American College of Rheumatology and 35th Annual Scientific Meeting of the Association of Rheumatology Health Professionals. 2000; Philadelphia, PA.
   Google Scholar
• Banner DW, D’Arcy A, Janes W, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell. 1993;73:431–445.
   Google Scholar
• Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008;58:1248–1257.
   Google Scholar
• Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356(9227):385–390.
   Google Scholar
• Ruddle NH. Lymphotoxin and TNF: how it all began – a tribute to the travelers. Cytokine Growth Factor Rev. 2014;25(2):83–89.
   Google Scholar
• Molinelli E, Campanati A, Ganzetti G, et al. Biologic therapy in immune mediated inflammatory disease: basic science and clinical concepts. Curr Drug Saf. 2016;11(1): 35–43. Review.
   Google Scholar
• Scallon BJ, Trinh H, Nedelman M, et al. Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins. Cytokine. 1995;7(8):759–770.
   Google Scholar
• Murdaca G, Colombo BM, Contini P, et al. Determination of lymphotoxin-alpha levels in patients with psoriatic arthritis undergoing etanercept treatment. J Interferon Cytokine Res. 2012;32(6):277–279.
   Google Scholar
• Buch MH, Conaghan PG, Quinn MA, et al. True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha? Ann Rheum Dis. 2004;63(Suppl 10):1344–1346.
   Google Scholar
• Thomson A. Etanercept in psoriasis: the evidence of its therapeutic impact. Core Evid. 2007;2(1):51–62.
   Google Scholar
• Marotte H, Cimaz R. Etanercept - TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers? Expert Opin Biol Ther. 2014;14(5):569–572.
   Google Scholar
• Simponi® (golimumab) [information]. Horsham, PA: Janssen Biotech, Inc; 2018.
   Google Scholar
• Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev. 2002;54:531–545.
   Google Scholar
• Campanati A, Benfaremo D, Luchetti MM, et al. Certolizumab pegol for the treatment of psoriasis. Expert Opin Biol Ther. 2017;17(3):387–394.
   Google Scholar
• Palframan R, Airey M, Moore A, et al. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods. 2009;348(1–2):36–41.
   Google Scholar
• Goel N, Stephens S. Certolizumab pegol. MAbs. 2010;2(2):137–147.
   Google Scholar
• Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other antitumour necrosis factor α agents. Inflamm Bowel Dis. 2007;13:1323–1332.
   Google Scholar
• Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228–233.
   Google Scholar
• Cimzia ® [prescribing information]. Smyrna, GA: UCB, Inc.; 2019.
   Google Scholar
• Lucka TC, Pathirana D, Sammain A, et al. Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment. J Eur Acad Dermatol Venereol. 2012;26(11):1331–1344.
   Google Scholar
• Papp KA, Lebwohl MG. Onset of action of biologics in patients with moderate-to-severe psoriasis. J Drugs Dermatol. 2017;17(3): 247–250. Review.
   Google Scholar
• Nast A, Sporbeck B, Rosumeck S, et al. Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action. J Invest Dermatol. 2013;133(8):1963–1970.
   Google Scholar
• Puig L, López A, Vilarrasa E, et al. Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points. J Eur Acad Dermatol Venereol. 2014;28(12):1633–1653.
   Google Scholar
• Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British association of dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017 Sep;177(3):628–636.
   Google Scholar
• Cline A, Hill D, Lewallen R, et al. Current status and future prospects for biologic treatments of psoriasis. Expert Rev Clin Immunol. 2016;12(12):1273–1287.
   Google Scholar
• Galvan-Banqueri M, Marin Gil R, Santos Ramos B, et al. Biological treatments for moderate-to-severe psoriasis: indirect comparison. J Clin Pharm Ther. 2013;38(2):121–130.
   Google Scholar
• Murdaca G, Negrini S, Magnani O, et al. Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis. Expert Opin Drug Saf. 2017;16(10):1173–1179.
   Google Scholar
• Murdaca G, Gulli R, Spanò F, et al. Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept? Drug Dev Res. 2014;75 Suppl 1:S7–S10.
   Google Scholar
• Murdaca G, Spanò F, Contatore M, et al. Pharmacogenetics of etanercept: role of TNF-alpha gene polymorphisms in improvement its efficacy. Expert Opin Drug Metab Toxicol. 2014;10(12):1703–1710.
   Google Scholar
• Murdaca G, Gulli R, Spanò F, et al. TNF-α gene polymorphisms: association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis. J Invest Dermatol. 2014;134(10):2503–2509.
   Google Scholar
• Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118–128.
   Google Scholar
• Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386:541–551.
   Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis results of two phase 3 trials. N Engl J Med. 2014;371:326–338.
   Google Scholar
• Papini M, Cusano F, Romanelli M, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study. Br J Dermatol. 2019;181(2):413–414.
   Google Scholar
• Magnano M, Loi C, Patrizi A, et al. Secukinumab in multi-failure psoriatic patients: the last hope? J Dermatolog Treat. 2018;29(6):583–585.
   Google Scholar
• Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31:774–790.
   Google Scholar
• Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicenter, double-blind trial. Lancet. 2005;366:1367–1374.
   Google Scholar
• Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106–115.
   Google Scholar
• Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. Lancet. 2006;367:29–35.
   Google Scholar
• Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-expert review of clinical immunology 1285 controlled study. Arthritis Rheum. 2009;60(4):976–986.
   Google Scholar
• Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73:48–55.
   Google Scholar
• Bertolini DR, Nedwin GE, Bringman TS, et al. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature. 1986 Feb 6–12;319(6053):516–518.
   Google Scholar
• Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature. 1986;322(6079):547–549.
   Google Scholar
• Köhm M, Burkhardt H, Behrens F. Anti-TNFα-therapy as an evidence-based treatment option for different clinical manifestations of psoriatic arthritis. Clin Exp Rheumatol. 2015 Sep-Oct;33(5Suppl 93):S109–14. Epub 2015. Review
   Google Scholar
• Partsch G, Steiner G, Leeb BF, et al. Highly increased levels of tumor necrosis factor alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol. 1997;24(3):518–523.
   Google Scholar
• Husby G, Williams RS Jr. Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun. 1988;1:363–371.
   Google Scholar
• Cañete JD, Celis R, Yeremenko N, et al. Ectopic lymphoid neogenesis is strongly associated with activation of the IL-23 pathway in rheumatoid synovitis. Arthritis Res Ther. 2015;17:173.
   Google Scholar
• van Baarsen LG, Lebre MC, van der Coelen D, et al. Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? Arthritis Res Ther. 2014;16(4):426.
   Google Scholar
• Boutet MA, Nerviani A, Gallo Afflitto G, et al. Role of the IL-23/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints. Int J Mol Sci. 2018;19(2):530. Review.
   Google Scholar
• Belasco J, Louie JS, Gulati N, et al. Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis. Arthritis Rheumatol. 2015;67(4):934–944.
   Google Scholar
• Wallace EB, Khosravi H, Joyce CJ, et al. Examining the epidemiology of coincident psoriasis and sarcoidosis: an observational cross-sectional study. J Am Acad Dermatol. 2018;S0190–9622(18):32893–32897.
   Google Scholar
• Santalla Martínez M, Loureiro Martínez M. Sarcoidosis associated with psoriasis: 2 disease entities, one pathogenic pathway. Arch Bronconeumol. 2016;52(9):489–490.
   Google Scholar
• Petroianni A, Halili I, Lagalla M, et al. Sarcoidosis at onset of psoriasis: a common immunopathogenesis. Review and case report. Eur Rev Med Pharmacol Sci. 2015;19(10): 1773–1778. Review.
   Google Scholar
• Khalid U, Gislason GH, Hansen PR. Sarcoidosis in patients with psoriasis: a population-based cohort study. PLoS One. 2014;9(10):e109632.
   Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. N Engl J Med. 1997;337(15):1029–1035.
   Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2): 323–333. quiz 591.
   Google Scholar
• Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019 Jan;80(1):27–40.
   Google Scholar
• Mukhtyar C, Luqmani R. Current state of tumour necrosis factor {alpha}blockade in Wegener’s granulomatosis. Ann Rheum Dis. 2005;64(Suppl 4): iv31–6. Review.
   Google Scholar
• Malaviya R, Laskin JD, Laskin DL. Anti-TNFα therapy in inflammatory lung diseases. Pharmacol Ther. 2017;180:90–98.
   Google Scholar
• Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795–802.
   Google Scholar
• Tynjala P, Lindahl P, Honkanen V, et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66:548–550.
   Google Scholar
• Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91:319–324.
   Google Scholar
• Ueda N, Tsukamoto H, Mitoma H, et al. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α. Ann Rheum Dis. 2012;71(Suppl 3):665.
   Google Scholar
• Chimenti MS, Saraceno R, Chiricozzi A, et al. Profile of certolizumab and its potential in the treatment of psoriatic arthritis. Drug Des Devel Ther. 2013;7:339–348. Published 2013.
   Google Scholar
• Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum. 2009;60:1884–1894.
   Google Scholar
• Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev. 2015;14(6):503–509.
   Google Scholar
• Amerio P, Amoruso G, Bardazzi F, et al. Detection and management of latent tuberculosis infections before biologic therapy for psoriasis. J Dermatolog Treat. 2013;24(4):305–311.
   Google Scholar
• Gisondi P, Cazzaniga S, Chimenti S, et al. Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian psocare registry. Br J Dermatol. 2015;172(6):1613–1620.
   Google Scholar
• Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology. 2005;129(3):827–836.
   Google Scholar
• Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn’s disease. J Eur Acad Dermatol Venereol. 2009;23(5):561–565.
   Google Scholar
• Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol. 2000;42:829–830.
   Google Scholar
• Tan MH, Gordon M, Lebwohl O, et al. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol. 2001;137:930–933.
   Google Scholar
• Garber K. Anti-IL-17 mAbs herald new options in psoriasis. Nat Biotechnol. 2012;30:475–477.
   Google Scholar
• Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006;116:1310–1316.
   Google Scholar
• O’Connor W Jr, Kamanaka M, Booth CJ, et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol. 2009;10:603–609.
   Google Scholar
• Awasthi A, Kuchroo VK. IL-17A directly inhibits TH1 cells and thereby suppresses development of intestinal inflammation. Nat Immunol. 2009;10:568–570.
   Google Scholar
• Tang C, Kakuta S, Shimizu K, et al. Suppression of IL-17F, but not of IL-17A, provides protection against colitis by inducing T(reg) cells through modification of the intestinal microbiota. Nat Immunol. 2018;19(7):755–765.
   Google Scholar
• Mengesha BG, Conti HR. The role of IL-17 in protection against mucosal candida infections. J Fungi (Basel). 2017;3(4): 52. Published 2017.
   Google Scholar
• Standaert-Vitse A, Jouault T, Vandewalle P, et al. Candida albicans is an immunogen for anti-saccharomyces cerevisiae antibody markers of Crohn’s disease. Gastroenterology. 2006;130(6):1764–1775.
   Google Scholar
• Poulain D, Sendid B, Standaert-Vitse A, et al. Yeasts: neglected pathogens. Dig Dis. 2009;27(Suppl 1):104–110.
   Google Scholar
• Colombel JF, Sendid B, Jouault T, et al. Secukinumab failure in Crohn’s disease: the yeast connection? Gut. 2013;62:800–801.
   Google Scholar
• Kolho KL, Korpela K, Jaakkola T, et al. Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation. Am J Gastroenterol. 2015;110:921–930.
   Google Scholar
• Scher JU, Ubeda C, Artacho A, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol. 2015;67(1):128–139.
   Google Scholar
• Benhadou F, Mintoff D, Schnebert B, et al. Psoriasis and microbiota: a systematic review. Diseases. 2018;6(2): 47. Published 2018.
   Google Scholar
• Wu X, Liu J, Xiao L, et al. Alterations of gut microbiome in rheumatoid arthritis. Osteoarthr Cartil. 2017;25:S287–S288.
   Google Scholar
• Cao Y, Shen J, Ran ZH. Association between faecalibacterium prausnitzii reduction and inflammatory bowel disease: a meta-analysis and systematic review of the literature. Gastroenterol Res Pract. 2014;2014:872725.
   Google Scholar
• Picchianti-Diamanti A, Panebianco C, Salemi S, et al. Analysis of gut microbiota in rheumatoid arthritis patients: disease-related dysbiosis and modifications induced by etanercept. Int J Mol Sci. 2018;19:10.
   Google Scholar
• Bazin T, Hooks KB, Barnetche T, et al. Microbiota composition may predict anti-tnf alpha response in spondyloarthritis patients: an exploratory study. Sci Rep. 2018;8(1):5446.
   Google Scholar
• Campanati A, Molinelli E, Brisigotti V, et al. Biologic therapy in psoriasis (Part I): efficacy and safety of tumor necrosis factor- α inhibitors. Curr Pharm Biotechnol. 2017;18(12):945–963.
   Google Scholar
• Grozdev IS, Van Voorhees AS, Gottlieb AB, et al. Psoriasis in the elderly: from the medical board of the national psoriasis foundation. J Am Acad Dermatol. 2011;65(3):537–545.
   Google Scholar
• Feldman SR, Koo JY, Menter A, et al. Decision points for the initiation of systemic treatment for psoriasis. J Am Acad Dermatol. 2005;53:101–107.
   Google Scholar
• Møller AH, Erntoft S, Vinding GR, et al. A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values. Patient Relat Outcome Meas. 2015;6:167–177.
   Google Scholar
• Medina C, Carretero G, Ferrandiz C, et al. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry. J Eur Acad Dermatol Venereol. 2015;29(5):858–864.
   Google Scholar
• Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF, et al. Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis. Arthritis Res Ther. 2012;14(4): R160. Published 2012.
   Google Scholar
• Merlo G, Cozzani E, Burlando M, et al. Effects of TNF-α inhibitors in patients with psoriasis and metabolic syndrome: a preliminary study. G Ital Dermatol Venereol. 2017. doi: 10.23736/S0392-0488.17.05621-8. Epub ahead of print.
   Google Scholar
• Ganzetti G, Campanati A, Scocco V, et al. The potential effect of the tumour necrosis factor-α inhibitors on vitamin D status in psoriatic patients. Acta Derm Venereol. 2014;94(6):715–717.
   Google Scholar
• Campanati A, Molinelli E, Ganzetti G, et al. The effect of low-carbohydrates calorie-restricted diet on visceral adipose tissue and metabolic status in psoriasis patients receiving TNF-alpha inhibitors: results of an open label controlled, prospective, clinical study. J Dermatolog Treat. 2017;28(3):206–212.
   Google Scholar
• Murdaca G, Spanò F, Cagnati P, et al. Free radicals and endothelial dysfunction: potential positive effects of TNF-α inhibitors. Redox Rep. 2013;18(3):95–99.
   Google Scholar
• Campanati A, Ganzetti G, Giuliodori K, et al. Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor-α inhibitors: results of a retrospective analysis. Int J Dermatol. 2015;54(7):839–845.
   Google Scholar
• Bacchetti T, Campanati A, Ferretti G, et al. Oxidative stress and psoriasis: the effect of antitumour necrosis factor-α inhibitor treatment. Br J Dermatol. 2013;168(5):984–989.
   Google Scholar
• Marra M, Campanati A, Testa R, et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol. 2007;20(4):731–736.
   Google Scholar
• Wu JJ, Poon KY, Channual JC, et al. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148:1244–1250.
   Google Scholar
• Nguyen T, Wu JJ. Relationship between tumor necrosis factor-α inhibitors and cardiovascular disease in psoriasis: a review. Perm J. 2014;18(1):49–54.
   Google Scholar
• Puig L. Cardiometabolic comorbidities in psoriasis and psoriatic arthritis. Int J Mol Sci. 2017;19(1): 58. Published 2017.
   Google Scholar
• Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and cochrane overview. Cochrane Database Syst Rev. 2011;(2):CD008794. doi: 10.1002/14651858.CD008794.pub2. Review.
   Google Scholar
• Suissa S, Ernst P, Hudson M. TNF-alpha antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2008;21(1): 234–238. Epub 2007.
   Google Scholar
• Campanati A, Moroncini G, Ganzetti G, et al. Adalimumab modulates angiogenesis in psoriatic skin. Eur Journal Inflam. 2013;11(2):489–498.
   Google Scholar
• Busti AJ, Hooper JS, Amaya CJ, et al. Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing. Pharmacotherapy. 2005;25(11):1566–1591.
   Google Scholar
• Den Broeder AA, Creemers MC, Fransen J, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol. 2007;34(4):689–695.
   Google Scholar
• Berthold E, Geborek P, Gülfe A. Continuation of TNF blockade in patients with inflammatory rheumatic disease. An observational study on surgical site infections in 1,596 elective orthopedic and hand surgery procedures. Acta Orthop. 2013;84(5):495–501.
   Google Scholar
• Shan J, Zhang J. Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: a systematic review and meta-analysis. Joint Bone Spine. 2019;86(2):173–183.
   Google Scholar
• Dotan I, Ron Y, Yanai H, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014;20(12):2247–2259.
   Google Scholar
• Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46(8): 645–660. Review.
   Google Scholar
• Clowse ME, Forger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76:1890–1896.
   Google Scholar
• Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013;108:1426–1438.
   Google Scholar
• Nielsen OH, Maxwell C, Hendel J. IBD medications during pregnancy and lactation. Nat Rev Gastroenterol Hepatol. 2014;11:116–127.
   Google Scholar
• Forger F, Zbinden A, Villiger PM. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients. Joint Bone Spine. 2016;83:341–343.
   Google Scholar
• Nguyen GC, Seow CH, Maxwell C, et al. The toronto consensus statements for the management of IBD in pregnancy. Gastroenterology. 2016;150:734–757.
   Google Scholar
• van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9:107–124.
   Google Scholar
• Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford). 2016;55:1693–1697.
   Google Scholar
• Gotestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795–810.
   Google Scholar
• Amin M, No DJ, Egeberg A, et al. Choosing first-line biologic treatment for moderate-to-severe psoriasis: what does the evidence say? Am J Clin Dermatol. 2018;19:1–13.
   Google Scholar
• Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: systematic review and meta-analysis. JAMA Intern Med. 2013;173(15):1416–1428.
   Google Scholar
• Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305(14):1460–1468.
   Google Scholar
• Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol. 2014;170(2):261–273.
   Google Scholar
• Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut. 2007;56(9):1226–1231.
   Google Scholar
• Lichtenstein L, Ron Y, Kivity S, et al. Infliximab-related infusion reactions: systematic review. J Crohns Colitis. 2015;9(9):806–815.
   Google Scholar
• Moustou AE, Matekovits A, Dessinioti C, et al. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol. 2009;61(3):486–504.
   Google Scholar
• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–850.
   Google Scholar
• Dommasch ED, Abuabara K, Shin DB, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64:1035–1050.
   Google Scholar
• Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152(6):1297–1309.
   Google Scholar
• Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301(7):737–744.
   Google Scholar
• Bardazzi F, Magnano M, Campanati A, et al. Biologic therapies in HIV-infected patients with psoriasis: an Italian experience. Acta Derm Venereol. 2017;97(8): 989–990. 31.
   Google Scholar
• Barcellos LF, Kamdar BB, Ramsay PP, et al. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. Lancet Neurol. 2006;5(11):924–931.
   Google Scholar
• Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M. Biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2013;25(1):56–64.
   Google Scholar
• Kemanetzoglou E, Andreadou E. CNS demyelination with TNF-α blockers. Curr Neurol Neurosci Rep. 2017;17(4):36.
   Google Scholar
• Setoguchi S, Schneeweiss S, Avorn J, et al. Tumor necrosis factor-(alpha) antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J. 2008;156:336–341.
   Google Scholar
• EMEA public statement on infliximab (Remicade ®). London; 2001 October 24.
   Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(21): 2482. 7.
   Google Scholar
• Klein A, Polliack A, Gafter-Gvili A. Rheumatoid arthritis and lymphoma: incidence, pathogenesis, biology, and outcome. Hematol Oncol. 2018;36(5): 733–739. Epub 2018 Jun 3. Review.
   Google Scholar
• Lebrec H, Ponce R, Preston BD, et al. Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk. Curr Med Res Opin. 2015 Mar;31(3):557–574.
   Google Scholar
• Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis. 2007;13(8):1024–1030.
   Google Scholar
• Nardone B, Hammel JA, Raisch DW, et al. Melanoma associated with tumour necrosis factor-α inhibitors: a research on adverse drug events and reports (RADAR) project. Br J Dermatol. 2014;170(5):1170–1172.
   Google Scholar
• Scott FI, Mamtani R, Brensinger CM, et al. Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and non-melanoma skin cancer. JAMA Dermatol. 2016;152(2):164–172.
   Google Scholar
• Vasconcellos JB, Pereira DD, Vargas TJ, et al. Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis. An Bras Dermatol. 2016;91(5 suppl 1):137–139.
   Google Scholar
• Wollina U, Hansel G, Koch A, et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9(1):1–14.
   Google Scholar
• Conrad C, Di Domizio J, Mylonas A, et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun. 2018;9(1):25.
   Google Scholar
• Almoallim H, Al-Ghamdi Y, Almaghrabi H, et al. Anti-tumor necrosis factor-α induced systemic lupus erythematosus(). Open Rheumatol J. 2012;6:315–319.
   Google Scholar
• Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford). 2009 Jul;48(7):716–720.
   Google Scholar
• Sarzi-Puttini P, Atzeni F, Capsoni F, et al. Drug-induced lupus erythematosus. Autoimmunity. 2005;38(7):507–518.
   Google Scholar
• Béné J, Moulis G, Auffret M, et al. Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database. Rheumatology (Oxford). 2014;53(8):1465–1469.
   Google Scholar
• Offidani A, Campanati A. The biologics in clinical practice: A modern approach for inflammatory and immune-mediated diseases. Curr Drug Saf. 2016;11(1):3.
   Google Scholar
• Piaserico S, Cazzaniga S, Chimenti S, et al. Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian psocare registry. J Am Acad Dermatol. 2014;70(2):257–62.e3.
   Google Scholar
• Campanati A, Offidani A. The biologic era: a comprehensive approach for inflammatory and immune-mediated diseases. Curr Pharm Biotechnol. 2017;18(12):944.
   Google Scholar
• Linder D, Altomare G, Amato S, et al. PSOCUBE, a multidimensional assessment of psoriasis patients as a both clinically/practically sustainable and evidence-based algorithm. J Eur Acad Dermatol Venereol. 2015;29(7):1310–1317.
   Google Scholar
• Luchetti MM, Benfaremo D, Campanati A, et al. Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two-year clinical experience of a dermo-rheumatologic clinic. A Clin Rheumatol. 2018;37(10):2741–2749.
   Google Scholar